Inhibition of Scarring Fibrosis and Neovascularization After Corneal Injury
Abstract
The goals of this funded project are: 1) To test the hypothesis that topical losartan, as well as one of the other ACEII inhibitor family members tested, will effectively inhibit anterior stromal fibrosis and stromal CNV after simulated blast injury to the cornea or corneo-limbal incisions simulating lacerations in rabbit models. 2) To determine if higher topical losartan concentrations in balanced salt solution of 8 mg/ml or 40 mg/ml six times per day can significantly decrease corneal scarring fibrosis and stromal neovascularization after alkali burns in a rabbit model compared to 0.8 mg/ml topical losartan without major increases in ocular surface complications or decrease the amount of time treatment is needed to treat corneal scarring fibrosis. 3) To determine if topical losartan can be given after corneal fibrosis has already become established and still be effective in decreasing stromal scarring fibrosis, and 4) That combined treatment with both topical losartan and topical Axitinib will have a greater effect in inhibiting CNV after corneal alkali burn injury in rabbits than either agent alone.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1223333
Entities
People
- Steven E. Wilson